» Articles » PMID: 26835318

Wilms' Tumor: Biology, Diagnosis and Treatment

Overview
Journal Transl Pediatr
Specialty Pediatrics
Date 2016 Feb 3
PMID 26835318
Citations 68
Authors
Affiliations
Soon will be listed here.
Abstract

Wilms' tumor is the commonest renal tumor of childhood affecting one in 10,000 children. It is also one of the successes of paediatric oncology with long term survival above 90% for localised disease and 75% for metastatic disease. Successful management of Wilms' tumor necessitates meticulous attention to correct staging of the tumor and a collaborative effort between paediatric oncologists, specialist surgeons, radiologists, pathologists, and radiation oncologists. Although current treatment protocols are based on risk assignment to minimise toxicity for low risk patients and improve outcomes for those with high risk disease, challenges remain in identifying novel molecular, histological and clinical risk factors for stratification of treatment intensity. Knowledge about Wilms' tumor biology and treatment is evolving rapidly and remains a paradigm for multimodal malignancy treatment. Future efforts will focus on the use of biomarkers to improve risk stratification and the introduction of newer molecularly targeted therapies that will minimise toxicity and improve the outcomes for patients with unfavourable histology and recurrent disease. The aim of this article is to summarise advances in our understanding of the biology of Wilms' tumor and to describe the current approaches to clinical management of patients.

Citing Articles

Long-term kidney outcomes in survivors of Wilms tumor: a single-center retrospective cohort study.

Reinert S, Benoit S, Nagarajan R Pediatr Nephrol. 2025; .

PMID: 39779510 DOI: 10.1007/s00467-024-06624-x.


Rare cases of a second recurrence of nephroblastoma with MLLT1 gene mutation: case report and literature review.

Dai Y, Chen X, He G, Gao J, Guo X Front Oncol. 2024; 14:1487544.

PMID: 39687897 PMC: 11646860. DOI: 10.3389/fonc.2024.1487544.


Methylation changes and INS-IGF2 expression predict progression in early-stage Wilms tumor.

Jalal D, Ali M, Elkinaai N, Abdelaziz A, Zekri W, A Sayed A Clin Epigenetics. 2024; 16(1):170.

PMID: 39593106 PMC: 11590261. DOI: 10.1186/s13148-024-01775-y.


Inter-Ethnic Variations in the Clinical, Pathological, and Molecular Characteristics of Wilms Tumor.

Lim K, Loh A Cancers (Basel). 2024; 16(17).

PMID: 39272909 PMC: 11393868. DOI: 10.3390/cancers16173051.


Worse Wilms' Tumor Outcomes Associated With Chemical Complementarity for Multiple T-Cell Receptor CDR3-CMV Epitope Pairs.

Rigby K, Diaz M, Gozlan E, Kacsoh D, Song J, Hudock T Cancer Genomics Proteomics. 2024; 21(5):439-447.

PMID: 39191494 PMC: 11363928. DOI: 10.21873/cgp.20462.


References
1.
Ritchey M, Green D, Thomas P, Smith G, Haase G, Shochat S . Renal failure in Wilms' tumor patients: a report from the National Wilms' Tumor Study Group. Med Pediatr Oncol. 1996; 26(2):75-80. DOI: 10.1002/(SICI)1096-911X(199602)26:2<75::AID-MPO1>3.0.CO;2-R. View

2.
Scott R, Walker L, Olsen O, Levitt G, Kenney I, Maher E . Surveillance for Wilms tumour in at-risk children: pragmatic recommendations for best practice. Arch Dis Child. 2006; 91(12):995-9. PMC: 2083016. DOI: 10.1136/adc.2006.101295. View

3.
Knudson Jr A . Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971; 68(4):820-3. PMC: 389051. DOI: 10.1073/pnas.68.4.820. View

4.
Buckley K . Pediatric genitourinary tumors. Curr Opin Oncol. 2011; 23(3):297-302. DOI: 10.1097/CCO.0b013e3283458613. View

5.
Wittmann S, Zirn B, Alkassar M, Ambros P, Graf N, Gessler M . Loss of 11q and 16q in Wilms tumors is associated with anaplasia, tumor recurrence, and poor prognosis. Genes Chromosomes Cancer. 2006; 46(2):163-70. DOI: 10.1002/gcc.20397. View